BIONTECH

We are advancing a diversified portfolio of product candidates derived from our four drug classes focused on the potential treatment of cancer, infectious diseases and other serious diseases of unmet patient need:

Oncology

Drug class	Platform	Product candidate	Indication (target)	Phase 1	Phase 1/2	Phase 2	Phase 3	BioNTech rights ⁽¹⁾	Collaborato / Partner
mRNA	FixVac	BNT111	Advanced, R/R melanoma						
		BNT113	Metastatic / R/R HPV16+ head and neck cancer					Fully owned ⁽²⁾	
		BNT116	1L metastatic NSCLC					Fully owned	
			Advanced/metastatic NSCLC						
	iNeST	BNT122 / RO7198457 (autogene cevumeran)	1L advanced melanoma						
			Adjuvant colorectal cancer						
			Adjuvant pancreatic ductal adenocarcinoma						Genentech ⁽
			Multiple solid tumors						
	RiboMabs	BNT142	Multiple solid tumors (CD3×CLDN6)					Fully owned	
	RiboCytokines	BNT152 + BNT153	Multiple solid tumors (IL-7, IL-2)					Fully owned	
Cell therapies	CAR T cells + CARVac	BNT211	Multiple solid tumors (CLDN6)					Fully owned	
	Neoantigen-based T cells	BNT221	Refractory metastatic melanoma					Fully owned	
Protein- based therapeutics	Next-generation immune checkpoint modulators	BNT311 / GEN1046 (acasunlimab)	aPD(L)1-R/R metastatic NSCLC (PD-L1×4-1BB)						
		BNT312 / GEN1042	Multiple solid tumors (CD40×4-1BB)						
		BNT314 / GEN1059	Multiple solid tumors (EpCAM×4-1BB)					Collaboration	Genmab
		BNT315 / GEN1055	Multiple solid tumors (OX40)						
		BNT322 / GEN1056	Multiple solid tumors						
		BNT316 / ONC-392 (gotistobart)	aPD(L)1-R/R metastatic NSCLC (CTLA-4) Platinum-resistant ovarian cancer (CTLA-4) Metastatic castration-resistant					Collaboration	OncoC4
			prostate cancer (CTLA-4) Multiple solid tumors (CTLA-4)						
		BNT327 / PM8002	1L/2L+ ES-SCLC (PD-L1 x VEGF-A)						
			1L/2L metastatic TNBC (PD-L1 x VEGF-A)					Collaboration	Biotheus
		BNT327 / PM8002 + BNT325 / DB-1305	Multiple solid tumors					Collaboration	Biotheus / Duality Biologics
	Targeted cancer antibodies	BNT321	Adjuvant pancreatic ductal adenocarcinoma (sLea)					Fully owned	
			Metastatic pancreatic cancer (sLea)					r any onnou	
	Antibody-drug conjugates	BNT323 / DB-1303 (trastuzumab pamirtecan)	HR+/HER2-low metastatic breast cancer (HER2)						
			Multiple solid tumors (HER2)					Collaboration	Duality
		BNT324 / DB-1311	Multiple solid tumors (B7H3)					Collaboration	Biologics
		BNT325 / DB-1305	Multiple solid tumors (TROP2)						
		BNT326 / YL202	Multiple solid tumors (HER3)					Collaboration	MediLink Therapeuti
SMI ⁽⁴⁾	Toll-like receptor binding	BNT411	Multiple solid tumors (TLR7)					Fully owned	

BIONTECH

We are advancing a diversified portfolio of product candidates derived from our four drug classes focused on the potential treatment of cancer, infectious diseases and other serious diseases of unmet patient need:

Infectious Diseases

Drug class	Product candidate	Indication	Phase 1	Phase 1/2	Phase 2	Phase 3	Commercial	BioNTech rights ⁽¹⁾	Collaborator/ Partner
mRNA	BNT162b2							Collaboration	Pfizer Fosun Pharma
	BNT162b5/6/7	COVID-19							
	BNT162b + BNT162b4								
	BNT162b2+BNT161	COVID-19 – Influenza combination						Collaboration	Pfizer
	BNT161	Influenza						Collaboration ⁽⁵⁾	Pfizer
	BNT163	HSV						Collaboration	University of Pennsylvania
	BNT164	Tuberculosis ⁽⁶⁾						Fully owned	Funded by Bill & Melinda Gates Foundation
	BNT165	Malaria						Fully owned	
	BNT166	Мрох						Fully owned	Funded by CEPI (7)
	BNT167	Shingles						Collaboration	Pfizer
Protein-based therapeutics	BNT331	Bacterial vaginosis						Fully owned	

(1) For further details about BioNTech's rights see quarterly reports under https://investors.biontech.de/financials-filings/quarterly-reports.

(2) FixVac platform is fully owned by BioNTech. The BNT111 and BNT116 Phase 2 trials are jointly conducted with Regeneron as part of a cost-sharing strategic collaboration.

(3) Genentech, a member of the Roche Group

(4) Small Molecule Immunomodulators

(5) Out-licensed to Pfizer

(6) Two Phase 1 clinical trials are ongoing (NCT05537038, Germany and NCT05547464, Republic of South Africa).

(7) Coalition for Epidemic Preparedness Innovations, or CEPI